When sales don't work, there's always begging -- at least that's what J.C. Penney (NYSE: JCP ) seems to think with a new advertising campaign that pleads with shoppers to return to the department store.
Although I think former CEO Ron Johnson's idea to go with an everyday-low-pricing strategy wasn't a bad one, the outcome was disastrous. Shoppers fled to rivals Macy's�and Kohl's,�and Penney's earnings were a disaster as it lost $985 million in 2012.
The strategy shift was based on the premise that consumers were smart enough to see through the shenanigans of raising prices only to lower them for a "sale." Johnson thought shoppers would prefer being able to shop anytime in his store and get a low price every day. He was wrong.
So Johnson was unceremoniously ousted and Penney is back to playing the same game as everyone else. Now it's offering up a cloying mea culpa of sorts to customers: We changed, you didn't like it, so we changed back -- please, please, please come back to us!
Top 5 Oil Companies To Own In Right Now: AstraZeneca PLC (AZN)
AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�� products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. On August 31, 2011, the Company completed the sale of the Astra Tech business to DENTSPLY International Inc. On June 19, 2012, the Company acquired Ardea Biosciences Inc (Ardea), a biotechnology company in San Diego, California. In July 2012, the Company acquired a portfolio of neuroscience assets from Link Medicine Corporation. In August 2012, Alliance Pharma plc�� wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands Paludrine, Avloclor and Savarine from AstraZeneca UK Limited. In August 2012, the Company and Bristol-Myers Squibb Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company. In June 2013, the Company acquired Pearl Therapeutics.
Cardiovascular
The Company�� marketed products include Crestor (rosuvastatin calcium), Atacand2 (candesartan cilexetil), Seloken/Toprol-XL (metoprolol succinate), Tenormin (atenolol), Plendil (felodipine), Zestril3 (lisinopril dihydrate), Brilinta/Brilique (ticagrelor), and Axanum, (acetylsalicylic acid (ASA). Crestor1 is a statin used for the treatment of dyslipidaemia and hypercholesterolemia. In some markets, it is also indicated to slow the progression of atherosclerosis and to re! duce the risk of first cardiovascular (CV) events. Atacand2 is an angiotensin II antagonist used for the 1st line treatment of hypertension and symptomatic heart failure. Seloken/Toprol-XL is a beta-blocker once-daily tablet used for 24-hour control of hypertension and for use in heart failure and angina.
Tenormin is a cardioselective beta-blocker used for hypertension, angina pectoris and other CV disorders. Plendil is a calcium antagonist used for the treatment of hypertension and angina. Zestril3 is an angiotensin-converting enzyme inhibitor used for the treatment of a wide range of CV diseases, including hypertension. Brilinta/Brilique is an oral antiplatelet for the treatment of acute coronary syndromes (ACS). Axanum is a fixed dose combination indicated for prevention of CV events in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers.
The Company�� marketed products for diabetes include Komboglyze ((saxagliptin and metformin HCl), Kombiglyze XR (saxagliptin and metformin XR) and Onglyza (saxagliptin). Komboglyze is an immediate release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with Type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets. Kombiglyze XR is an extended release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Onglyza is a DPP-IV inhibitor used for the treatment of Type 2 diabetes.
Gastrointestinal
AstraZeneca�� marketed products include Nexium (esomeprazole), Losec/Prilosec (omeprazole) and Entocort (budesonide). Nexium is a proton pump inhibitor (PPI) used for the treatment of acid-related diseases to offer clini! cal impro! vements over other PPIs and other treatments. Losec/Prilosec is used for the short-term and long-term treatment of acid-related diseases. Entocort is a corticosteroid used for the treatment of inflammatory bowel disease. Nexium is marketed in approximately 120 countries and is available in oral (tablet/capsules and oral suspension) and intravenous (i.v.) dosage forms for the treatment of acid-related diseases.
Infection
The Company�� marketed products include Merrem/Meronem (meropenem), Cubicin (daptomycin) and FluMist/Fluenz (influenza vaccine live, intranasal). Merrem/Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients. Cubicin is a cyclic lipopeptide anti-bacterial used for the treatment of serious infections in hospitalised patients. FluMist/Fluenz is an intranasal live, attenuated, trivalent influenza vaccine.
Neuroscience
AstraZeneca�� marketed products include Seroquel IR (quetiapine fumarate), Seroquel XR (an extended release formulation of quetiapine fumarate), Zomig (zolmitriptan), Diprivan (propofol), Vimovo (naproxen/esomeprazole magnesium), Naropin (ropivacaine), Xylocaine (lidocaine) and EMLA (lidocaine and prilocaine). Seroquel IR is an atypical anti-psychotic drug used for the treatment of schizophrenia and bipolar disorder (mania, depression and maintenance). Seroquel XR is used for the treatment of schizophrenia, bipolar disorder, MDD and in some territories for generalised anxiety disorder (GAD).
Zomig is used for the treatment of migraines with or without aura and Zomig Nasal Spray is indicated for the acute treatment of cluster. Diprivan is an intravenous general anaesthetic used in the induction and maintenance of general anaesthesia, for use in intensive care sedation and conscious sedation for surgical as well as diagnostic procedures. Vimovo is a fixed-dose combination of enteric-coated naproxen (an NSAID) with the gastroprotection of immediate release ! esomepraz! ole (a proton pump inhibitor) for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the developing of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Naropin is used as a long-acting local anaesthetic, for surgical anaesthesia and acute pain management. Xylocaine is a used short-acting local anaesthetic. EMLA is used as a local anaesthetic for topical application.
Oncology
AstraZeneca�� marketed products include Arimidex (anastrozole), Zoladex (goserelin acetate implant), Casodex (bicalutamide), Iressa (gefitinib), Faslodex (fulvestrant), Nolvadex (tamoxifen citrate) and Caprelsa (vandetanib). Arimidex is an aromatase inhibitor used for the treatment of early breast cancer. Zoladex, in one- and three-month depots, is a luteinising hormone-releasing hormone agonist used for the treatment of prostate cancer, breast cancer and certain benign gynaecological disorders. Casodex is an anti-androgen therapy used for the treatment of prostate cancer.
Advisors' Opinion:- [By Sean Williams]
Where investment dollars are headed
Caprelsa: AstraZeneca's (NYSE: AZN ) Caprelsa was approved to treat unresectable, locally advanced, or metastatic medullary thyroid cancer in April 2011. In trials, AstraZeneca's pill increased progression-free survival over the placebo and delivered an overall response rate of 44%, compared with just 1% for the placebo -- although it should be noted that all responses were partial. However, Caprelsa also comes with a laundry list of side effects that range from something as simple as rash, nausea, and hypertension, to having resulted in death from respiratory arrest and cardiac failure with arrhythmia.� Cometriq: Exelixis' (NASDAQ: EXEL ) Cometriq was approved last November to treat progressive metastatic medullary thyroid cancer. The capsules work by inhibiting multiple tyrosine kinases, which are crucial to blood vessel growth in solid and metastasizing tumors. In late-stage trials, patients receiving Cometriq demonstrated an astounding 11.2 months of progression-free survival compared with just four months for the placebo. Further, the objective response rate was 27% in the Cometriq arm and a goose egg for the placebo arm. Similar to AstraZeneca's Caprelsa, severe adverse reactions tended to increase for Cometriq users relative to the placebo.
Thyroid cancer is treated in nearly every case with a full or partial thyroid removal since the majority of thyroid cancers aren't aggressive. However, in those rare cases where surgery isn't an option or the disease has metastasized to other parts of the body, there are two drugs approved by the Food and Drug Administration to choose from.Just as we've witnessed with every previous cancer in this series, not every drug trial proves successful. Pfizer's (NYSE: PFE ) Sutent, for instance, is a very successful treatment for kidney cancer, gastrointestinal stromal tumors, and pancreatic endocrine tumors, but it didn't fare as wel
5 Best Low Price Stocks For 2014: Grupo Financiero Galicia S.A. (GGAL)
Grupo Financiero Galicia S.A. operates as a financial services holding company in Argentina. The company offers financial products and services, including collection and payment services, commercial credit cards, direct payroll deposits, capital market alternatives, foreign trade solutions, and corporate e-banking solutions; corporate debt transactions and securitization transactions; and e-collection and payment solutions to various agencies, municipalities, and universities. It also provides a range of financial products and services, such as transactions, loans, and investments; and checking and savings accounts, credit and debit cards, payroll direct deposits, insurance, and retirement and pension payments. In addition, the company offers mutual funds and in brokerage services; manages positions in foreign currency and government securities; acts as an intermediary and distributes financial instruments for institutional investors, corporate customers, and individuals; and enables customers to buy and sell securities on the Buenos Aires Stock Exchange. Further, it provides life insurance products, including employee benefit plans and credit related insurance; and property and casualty insurance products, such as home and ATM theft insurance. As of December 31, 2012, the company operated 257 full service banking branches and 1,676 ATMs and self-service terminals. Grupo Financiero Galicia S.A. was founded in 1905 and is based in Buenos Aires, Argentina.
Advisors' Opinion:- [By Federico Zaldua]
Grupo Financiero Galicia (GGAL), which was once owned by Rob Citrone's hedge fund Discovery Capital Management, owns one of Argentina's biggest private banks by deposits and the fastest growing within the banks that count with national presence. As a matter of fact, according to management, "the bank's estimated market share of loans to private sector was 9.10% growing 56 basis points from a year before and the market share of deposits from the private sector was 8.98% growing 28 basis points in the year."
5 Best Low Price Stocks For 2014: Spherix Inc (SPEX)
Spherix Incorporated (Spherix), incorporated on May 1, 1992, is a scientific research company. The Company is engaged in developing biopharmaceutical products and providing technical and regulatory consulting services to food, consumer products and pharmaceutical companies. The Company operates in two segments: Biospherics Incorporated (Biospherics), the Company's biotechnology research and development business, and Health Sciences, a technical and regulatory consulting business. The Company has created two wholly owned subsidiaries, Biospherics Incorporated and Spherix Consulting, Inc. (Spherix Consulting), for its two operating segments. The Company's Health Sciences contracts are in the name of Spherix Consulting, and the Company's patents are in the name of Biospherics Incorporated. Spherix provides management, strategic guidance, business development, marketing and other services to its subsidiaries. In September 2013, Spherix Incorporated closed on the acquisition of North South Holdings Inc.
Biospherics
The Company focuses its studies on treating high triglycerides and other dyslipidemias with a combination of D-tagatose and SPX-106, a licensed drug compound, which combination is referred to as SPX-106T. Spherix Consulting provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. Biospherics has also completed a global Phase III clinical trial investigating the use of D-Tagatose, a stereoisomer of fructose, as a treatment for glycemic control in patients with Type 2 diabetes.
Health Sciences
The Company's Health Sciences business provides technical and regulatory consulting services to biotechnology and pharmaceutical companies, as well as providing technical suppo! rt for its research and development activities. During the year ended December 31, 2011, Health Sciences provided services to 20 companies. The projects range from safety analyses of food ingredients to safety analyses of pharmaceutical manufacturing and dispensing equipment. Health Sciences is also monitoring and directing the clinical trials for Biospherics.
Advisors' Opinion:- [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]
Spherix Inc.(SPEX) on Thursday said that it is suing Cisco Inc.(CSCO) (CSCO), a leging that $43 billion in Cisco sales infringed on Spherix patents. Spherix–which described itself as an “intellectual property development company committed to the fostering and monetization of intellectual property”��aid Cisco infringes on 11 patents it acquired in December. Spherix shares rose 4.9% to $4.70 premarket.
5 Best Low Price Stocks For 2014: REX American Resources Corp (REX)
Rex American Resources Corporation (REX), incorporated in 1984, is a holding company to succeed to the entire ownership of three affiliated corporations, Rex Radio and Television, Inc., Stereo Town, Inc. and Kelly & Cohen Appliances, Inc. As of January 31, 2012, the Company had lease agreements, as landlord, for six owned former retail stores and had 16 vacant former retail properties. The Company also owns one former distribution center that is partially leased, partially occupied by its corporate office personnel and partially vacant. The Company is marketing these vacant properties to lease or sell. As of January 31, 2012, the Company invested in five ethanol production entities, two of which the Company has a majority ownership interest in. These properties include One Earth Energy, LLC, NuGen Energy, LLC, Patriot Renewable Fuels, LLC, Levelland Hockley County Ethanol, LLC, and one group consisting of Big River Resources, LLC-W Burlington, Big River Resources, LLC-Galva and Big River United Energy, LLC. It operates through two business segments: alternative energy and real estate.
On November 1, 2011, the Company acquired an additional 50% equity interest in NuGen Energy, LLC. In December 2011, Big River acquired a 100% interest in an ethanol production facility located in Boyceville, Wisconsin.
Alternative Energy
As of January 31, 2012, all of the entities the Company is invested in are operating except for Levelland Hockley County Ethanol, LLC (Levelland Hockley). As of January 31, 2011, the Company held a 74% interest in One Earth Energy, LLC. The plant has an annual nameplate capacity of 100 million gallons of ethanol and 320,000 tons of dried distillers grains (DDG). The Company owns a 23% interest in Patriot Renewable Fuels, LLC (Patriot). The plant is located in Annawan, Illinois and has a nameplate capacity of 100 million gallons of ethanol and 320,000 tons of DDG per year.
As of January 31, 2012, all of the entities the Company is in! vested in are operating except for Levelland Hockley County Ethanol, LLC (Levelland Hockley). As of January 31, 2011, the Company held a 74% interest in One Earth Energy, LLC. The plant has an annual nameplate capacity of 100 million gallons of ethanol and 320,000 tons of dried distillers grains (DDG). The Company owns a 23% interest in Patriot Renewable Fuels, LLC (Patriot). The plant is located in Annawan, Illinois and has a nameplate capacity of 100 million gallons of ethanol and 320,000 tons of DDG per year.
Levelland Hockley is located in Levelland, Texas. The plant has a nameplate capacity of 40 million gallons of ethanol and 135,000 tons of dried distillers grains (DDG) per year. The plant was shut down in January 2011. On January 31, 2011, the Company sold 814,000 of its membership units to Levelland Hockley, reducing its ownership interest in Levelland Hockley to 49%. As a result, it no longer has a controlling financial interest in Levelland Hockley.
Real Estate Operations
As of January 31, 2011, the Company had lease agreements, as landlord, for all or parts of eight owned former retail stores (88,000 square feet leased and 10,000 square feet vacant). It had 22 owned former retail stores (281,000 square feet) that were vacant as of January 31, 2011. The Company is marketing these vacant properties to lease or sell. In addition, one former distribution center is partially leased (266,000 square feet), partially occupied by its corporate office personnel (10,000 square feet) and partially vacant (190,000 square feet). A typical lease agreement has an initial term of five to twenty years with renewal options. Most of its lessees are responsible for a portion of maintenance, taxes and other executory costs.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on REX American Resources (NYSE: REX ) , whose recent revenue and earnings are plotted below. - [By Tristan R. Brown]
Three months ago I wrote that the stock performance YTD of independent ethanol producer Pacific Ethanol (PEIX) was an "aberration", especially in light of the performance of its industry peers' shares. The discrepancy between Pacific Ethanol's share price and those of its peers has only grown more pronounced since July (see figure). Green Plains Renewable Energy (GPRE) and REX American Resources (REX) have continued to greatly outperform the S&P 500. Even Biofuel Energy, which fell behind on its interest and debt payments over the summer and is facing a shareholder-ruining liquidation, has seen its share price perform significantly better than Pacific Ethanol's in 2013. The oddest part about the stock's performance over the last three months, however, is that the period has been marked by multiple positive announcements from the company. It late July it reported its first positive EPS in almost two years for Q2 (0.07). Its Q2 EBITDA of $3.8 million was its highest since Q4 2011. Its current ratio is well above its previous lows, its ratio of total assets to total liabilities is increasing, and its total shareholders' equity is at a 3-year high. Despite these improvements, the company's price/book ratio is a mere 0.77.
No comments:
Post a Comment